The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest and most diverse research and service providing instrument to study infectious diseases in Europe, from structural biology to clinical trials. Giving scientists access to the whole extent of our state of the art facilities, cutting edge services, advanced equipment and expertise, in an integrated way and with a common goal, will enable or accelerate the generation of new knowledge and intervention tools to ultimately help control SARS CoV 2 in particular, and epidemic prone pathogens in general, while avoiding fragmentation and duplication among European initiatives. Such a global and interdisciplinary approach is meant to allow the implementation of user projects that are larger, more ambitious and more impactful than the EU supported transnational activities that the consortium is used to run. Our proposition is ambitious but achievable in a timely fashion due to the relevance and previous experience of the partners that we have gathered and that have complementary fields of expertise, which addresses the need for an interdisciplinary effort. Leveraging all these existing strengths to develop synergies will create an additional value and enhance Europe capacity for controlling emerging or re emerging and epidemic infectious diseases, starting with the COVID 19 pandemic. Such a global and coordinated approach is consistent with the recommendations of the One Health concept and necessary to make significant contributions to solving complex societal problems like epidemics and pandemics.

China and the EU have a solid framework for successful collaboration aiming at tackling common global societal challenges, such as the progress of ageing society. In addition, China and the EU are determined to intensify their cooperation via several joint flagship initiatives in a number of focus areas including biotechnologies for human health. China has been third most important international partner country in the EU Framework Programme 7. However, the global health challenges are difficult to tackle unilaterally, the research landscape is still fragmented with partly divergent research priorities and there is a current tendency of decreased Chinese participation in the EU health programmes. Therefore, a continuous and sustainable health-related research and innovation dialogue between China and the EU has to be maintained and encouraged in order to highlight and leverage on cooperation possibilities of mutual benefit. SENET - Sino-European Health Networking Hub has two main objectives: Firstly, it aims to create a sustainable health networking and knowledge hub which facilitates favourable conditions for a constant and constructive dialogue between Chinese and EU research and innovation entities. Secondly, it intends to increase collaborative efforts addressing common health research and innovation challenges. SENET’s objectives are in line with the expected impacts of the call. It intends to enhance bi-lateral and multi-lateral cooperation between EU and China on health research and innovation topics. It is determined to increase higher participation of Chinese researchers in SC1 and future EU and Chinese joint health research programmes and consequently strengthen R&I cooperation in health research and innovation. SENET is composed of a multidisciplinary team of 5 EU and 4 Chinese professionals with a long track record in their relative fields of expertise as think tank, researchers, policy analysts and trainers in health innovation and research management.

TRANSVAC-DS project further builds on the outstanding success of EC-funded projects:TRANSVAC1 and TRANSVAC2 and proposes the establishment of a truly sustainable European vaccine infrastructure, which will build upon the lessons learned, activities and achievements of the TRANSVAC1/2 projects. Two infrastructure projects -TRANSVAC1 and TRANSVAC2- have been funded by the European Commission which -through the provision of state-of-the-art scientific-technical vaccine development services, technical training, and innovative vaccine research and development- have provided very significant support to European vaccine researchers and developers. Support has been, and is being provided to the development of human and veterinary prophylactic and therapeutic vaccines. The twenty-five partners in the TRANSVAC-DS consortium that will contribute to the outcome of the project represent ten EU Member States and Associated Countries and include leading organisations from the European vaccine R&D field. The main output of TRANSVAC-DS will be a conceptual design report that will describe in detail the maturity of the concept and be the basis for the establishment of a permanent and sustainable vaccine infrastructure of direct relevance to and benefit for Europe and further afield. As part of the design report, a five-year business plan will be delivered together with an implementation plan that will guide the further establishment of a sustainable European vaccine infrastructure.